Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-24-002440

← back to feed
Filed
Apr 16, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Apr 12, 2024 31.11M sh
Cash And Equivalents Q2 2024 · Feb 29, 2024 $37.14K
Cash And Equivalents Q2 2024 · Aug 31, 2023 $129.7K
Current Liabilities Q2 2024 · Feb 29, 2024 $2.52M
Current Liabilities Q2 2024 · Aug 31, 2023 $2.52M
Current Assets Q2 2024 · Feb 29, 2024 $163.92K
Current Assets Q2 2024 · Aug 31, 2023 $224.31K
Total Assets Q2 2024 · Feb 29, 2024 $163.92K
Total Assets Q2 2024 · Aug 31, 2023 $499.04K
Shares Diluted Q2 2024 · Feb 28, 2023 1.96M sh
Shares Diluted Q2 2024 · Feb 28, 2023 2.09M sh
Operating Cash Flow Q2 2024 · Feb 28, 2023 −$114.45K
Stockholders Equity Q2 2024 · Feb 28, 2023 −$2.01M
Stockholders Equity Q2 2024 · Nov 30, 2022 −$1.97M
Stockholders Equity Q2 2024 · Aug 31, 2022 −$1.63M
Eps Diluted Q2 2024 · Feb 28, 2023 −$1.33
Eps Diluted Q2 2024 · Feb 28, 2023 −$1.42
Eps Basic Q2 2024 · Feb 28, 2023 −$1.33
Eps Basic Q2 2024 · Feb 28, 2023 −$1.42
Sga Expense Q2 2024 · Feb 28, 2023 $237.68K
Sga Expense Q2 2024 · Feb 28, 2023 $521.59K
Rd Expense Q2 2024 · Feb 28, 2023 $12.33K
Rd Expense Q2 2024 · Feb 28, 2023 $75.22K
Net Income Q2 2024 · Feb 28, 2023 −$2.62M
Net Income Q2 2024 · Feb 28, 2023 −$2.98M
Operating Income Q2 2024 · Feb 28, 2023 −$250.01K
Operating Income Q2 2024 · Feb 28, 2023 −$596.8K
Gross Profit Q2 2024 · Feb 28, 2023 $0
Gross Profit Q2 2024 · Feb 28, 2023 $0
Cost Of Revenue Q2 2024 · Feb 28, 2023 $0
Cost Of Revenue Q2 2024 · Feb 28, 2023 $0
Revenue Q2 2024 · Feb 28, 2023 $0
Revenue Q2 2024 · Feb 28, 2023 $0